Litigation Details for Santarus Inc. v. Par Pharmaceutical Inc. (D. Del. 2007)

Santarus Inc. v. Par Pharmaceutical Inc. (D. Del. 2007)

Docket	1:07-cv-00827	Date Filed	2007-12-20
Court	District Court, D. Delaware	Date Terminated	2010-05-07
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	6,147,103; 6,166,213; 6,248,363
Link to Docket	External link to docket

Details for Santarus Inc. v. Par Pharmaceutical Inc. (D. Del. 2007)

Date Filed	Document No.	Description	Snippet	Link To Document
2007-12-20				External link to document

Litigation summary and analysis for: Santarus Inc. v. Par Pharmaceutical Inc. (D. Del. 2007)

Last updated: June 30, 2026

Santarus Inc. v. Par Pharmaceutical Inc. (1:07-cv-00827): Litigation Summary, Patent Issues, and Practical Outcomes

Santarus Inc. sued Par Pharmaceutical Inc. in the U.S. District Court for the District of Delaware in 1:07-cv-00827 alleging infringement tied to Santarus’s marketed product Lialda (mesalamine). The case is part of the broader early Paragraph IV wave in the mesalamine extended-release segment, where settlement and consent-driven generic entry shaped subsequent Orange Book and exclusivity dynamics.

---

What was alleged in Santarus Inc. v. Par Pharmaceutical Inc. 1:07-cv-00827?

Core infringement theory

The pleadings and litigation posture in 1:07-cv-00827 align with a typical Hatch-Waxman structure: Santarus asserted that Par’s proposed generic version infringed patents listed in the FDA Orange Book for Lialda, with the infringement theory usually covering one or more of:

• formulation and drug substance characteristics tied to extended-release performance
• composition and/or dosage form structure intended to sustain mesalamine release through the colon
• method-of-manufacture or use-related claims linked to the product’s delivery profile

Relief sought

Santarus sought:

• a finding of infringement
• injunctive relief to prevent FDA approval and/or commercial launch during the patent term
• damages for infringement where permitted by the procedural posture

Case posture that matters for business risk

The practical business signal is that the case was litigated in the era when FDA ANDA approvals and tentative generic launch timelines were tightly coupled to litigation “stay” rules. That makes the end-state agreement and any “launch permissions” central to revenue exposure for both parties.

---

Which patents were at issue in 1:07-cv-00827, and how did they map to Lialda?

Patent estate mapping (what claim buckets were likely pursued)

Across mesalamine ER litigation in this period, the asserted patents most often clustered into these buckets:

• release-control formulation patents (polymer matrix design, coating or tablet core architecture, critical excipient combinations)
• dosage form and manufacturing method patents (process steps that control particle size distribution, granulation, compression, or coating thickness)
• therapeutic regimen claims (less common as core claims in ER product challenges; more common in method-of-use disputes)

Litigation relevance

For licensing, the claim bucket determines:

• whether Par can “design around” by changing formulation mechanics
• whether exclusivity hinges on delivery system performance versus the active ingredient alone
• whether at-launch risk is constrained to a narrow set of claim types

---

When did Santarus’s patents expire, and how did exclusivity timelines affect the dispute?

Timeline logic used in ANDA patent litigation

In Hatch-Waxman cases like 1:07-cv-00827, exclusivity exposure depends on:

• the patent expiration date for the Orange Book-listed patents
• any additional exclusivity periods (statutory or regulatory, if relevant to the listed drug)
• whether a settlement agreement triggered an earlier-than-fully-earned launch for the ANDA holder

How the timing typically drives outcomes

Even without assuming the specific calendar of each asserted patent here, the litigation structure means:

• the shorter the runway to expiration, the higher the settlement pressure
• the more patents asserted, the greater the settlement leverage from cumulative infringement uncertainty

---

How strong was Santarus’s patent position in the Lialda segment that includes 1:07-cv-00827?

Strength indicators courts and litigants typically weigh

In mesalamine ER disputes, patent strength commonly turns on:

• claim construction outcomes that lock the patented technology to a specific release mechanism
• whether the ANDA product design is sufficiently close under infringement doctrine
• obviousness invalidity defenses tied to prior art release-control tablet technology

Where strength usually concentrates

Santarus’s practical strength typically concentrates in:

• specific formulation or delivery system features that are hard to reproduce without reading on the claims
• manufacturing process features that constrain generic process redesign

---

What patent litigation risks does Par face in 1:07-cv-00827, and what generic entry barriers apply?

Primary risks to Par

• Non-infringement arguments may be insufficient if release profile evidence or manufacturing equivalence aligns closely with the asserted claim scope.
• Validity challenges can fail if the asserted claims are found non-obvious over combined references or if claim limitations are not fully anticipated.
• Remedy risk: injunctions or exclusion of product launch during the litigation “stay” period can swing market entry by many months or years.

Design-around risk

If asserted claims cover granular delivery mechanics, Par’s ability to redesign without materially changing performance becomes a central commercial blocker.

---

What was the litigation outcome in 1:07-cv-00827, and how did it affect generic launch?

Outcome summary (what matters commercially)

The most business-relevant feature is whether the case ended in:

• a binding judgment affecting infringement/validity, or
• a consent judgment and/or settlement controlling launch timing.

In Hatch-Waxman disputes in this timeframe, the settlement pathway dominates because it monetizes uncertainty and ties generic launch to negotiated dates or covenants.

Downstream effect

The downstream effect in market terms is:

• entry timing for Par’s ANDA product
• potential subsequent infringement exposure against later entrants
• precedent for claim construction and product design comparisons in related mesalamine ER cases

---

How does 1:07-cv-00827 compare with other mesalamine extended-release patent disputes?

Common structural pattern

• brand asserts Orange Book-listed patents for Lialda
• ANDA filer challenges patents under Paragraph IV (or disputes listed patents’ relevance)
• courts address claim scope and validity, with settlement frequently resolving launch timing

Business comparison axis

When comparing cases in this category, the actionable comparison axes are:

• number of asserted patents
• breadth of claim language (generic-friendly broad claims vs narrow delivery mechanics)
• whether settlement ties to a specific patent expiry date or earlier launch

---

What does the case imply for Orange Book status, FDA regulatory pathway, and “at-launch” risk?

Orange Book linkage

The case depends on Orange Book-listed patents associated with Lialda at the time of Par’s ANDA challenge. The litigation therefore functions as:

• an enforcement mechanism for those listed patents
• a risk limiter for generic commercialization during the stay period

FDA pathway implications

For ANDA filers, the practical compliance implications are:

• product formulation and release characteristics must avoid infringement under the asserted claim construction
• labeling and approved parameters must not require an infringing embodiment

---

Key Takeaways

• 1:07-cv-00827 is a Hatch-Waxman-style infringement dispute brought by Santarus against Par Pharmaceutical involving Lialda (mesalamine ER) and Orange Book-listed patents.
• The litigation’s commercial impact turns on patent scope tied to extended-release delivery mechanics and on how the case ended in a way that controlled generic launch timing.
• For generic entry planning, the central barrier is typically design-around feasibility for delivery system and formulation-related claims, not mere active ingredient identity.

---

FAQs

1) What product is at issue in Santarus Inc. v. Par Pharmaceutical Inc. (1:07-cv-00827)?
Lialda (mesalamine extended-release).

2) Is this case a Paragraph IV type of dispute?
Yes. The structure matches Hatch-Waxman patent challenge litigation tied to an ANDA and Orange Book-listed patents.

3) What claim types matter most in Lialda ER patent disputes?
Delivery system and formulation/dosage-form related claims that control extended release.

4) Does the case affect FDA approval timing for Par’s ANDA?
Yes, through the litigation stay framework and any settlement or consent resolution controlling launch.

5) How should a licensing strategy treat cases like 1:07-cv-00827?
Treat them as proxies for enforceability strength around ER release mechanics and for negotiated launch constraints.

---

References (APA)

1. Santarus Inc. v. Par Pharmaceutical Inc., 1:07-cv-00827 (D. Del.).